CAMBRIDGE, Mass., March 20, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare diseases, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for lomitapide, a once-daily, oral treatment for Homozygous Familial Hypercholesterolemia (HoFH). Acceptance of the MAA starts the EMA's review process. Aegerion is seeking authorization to market lomitapide as an adjunct to a low fat diet and other lipid-lowering therapies to reduce cholesterol in patients with HoFH.
